Mylan Labs Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Mylan Labs

MYL 15.86

0.0%

Nov 19 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rhoffman who wrote (329)	7/1/1998 11:22:00 AM
From: David Lawrence	Read Replies (1) of 384

PITTSBURGH--(BUSINESS WIRE)--July 1, 1998--Mylan Laboratories Inc. (NYSE:MYL) announced today that it has received approval to manufacture and market Glyburide tablets in 1.5 and 3 mg strengths. This generic version of Pharmacia and Upjohn's Glynase(R) Prestab(R) is used as an adjunct to diet to lower the blood glucose in patients with non-insulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone. Mylan is manufacturing this antidiabetic product in its Morgantown, West Virginia plant. The product is being shipped immediately.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next